Functional polymorphisms in carboxylesterase 1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites

Biochemical and Biophysical Research Communications

Volumn 369, Issue 3, 2008, Pages 939-942

  Yoshimura, Mika ^a   Kimura, Tomomi ^a   Ishii, Miho ^b   Ishii, Keisuke ^b   Matsuura, Tadashi ^b   Geshi, Eiichi ^c   Hosokawa, Masakiyo ^d   Muramatsu, Masaaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b HuBit Genomix Research Institute   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CHIBA INSTITUTE OF SCIENCE   (Japan)

Author keywords

Carboxylesterase; CES; CES1A2; Haplotype; HU1b; Imidapril; Polymorphism; Promoter; SNP; Sp1

Indexed keywords

CARBOXYLESTERASE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENE PRODUCT; IMIDAPRIL; PRODRUG; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; CARBOXYLESTERASE; CARBOXYLESTERASE 1A2, HUMAN; IMIDAZOLIDINE DERIVATIVE;

ARTICLE; BINDING SITE; CARBOXYLESTERASE 1A2 GENE; CONTROLLED STUDY; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HAPLOTYPE; HUMAN; HUMAN CELL; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; METABOLIC ACTIVATION; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; AMINO ACID SEQUENCE; ASIAN; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

AMINO ACID SEQUENCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; BINDING SITES; CARBOXYLESTERASE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE FREQUENCY; HAPLOTYPES; HUMANS; IMIDAZOLIDINES; LINKAGE DISEQUILIBRIUM; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SP1 TRANSCRIPTION FACTOR;

EID: 41149147459     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.02.120     Document Type: Article

References (10)

1. Satoh T., Taylor P., Bosron W.F., Sanghani S.P., Hosokawa M., and La Du B.N. Current progress on esterases: from molecular structure to function. Drug Metab. Dispos. 30 (2002) 488-493
2. Satoh T., and Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 257-288
3. Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13 (2008) 412-431
4. Yan B., Matoney L., and Yang D. Human carboxylesterases in term placentae: enzymatic characterization, molecular cloning and evidence for the existence of multiple forms. Placenta 20 (1999) 599-607
5. Langmann T., Becker A., Aslanidis C., Notka F., Ullrich H., Schwer H., and Schmitz G. Structural organization and characterization of the promoter region of a human carboxylesterase gene. Biochim. Biophys. Acta 1350 (1997) 65-74
6. Saito S., Iida A., Sekine A., Kawauchi S., Higuchi S., Ogawa C., and Nakamura Y. Catalog of 680 variations among eight cytochrome p450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J. Hum. Genet. 48 (2003) 249-270
7. Geshi E., Kimura T., Yoshimura M., Suzuki H., Koba S., Sakai T., Saito T., Koga A., Muramatsu M., and Katagiri T. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens. Res. 28 (2005) 719-725
8. Song J.C., and White C.M. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin. Pharmacokinet. 41 (2002) 207-224
9. Takai S., Matsuda A., Usami Y., Adachi T., Sugiyama T., Katagiri Y., Tatematsu M., and Hirano K. Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol. Pharm. Bull. 20 (1997) 869-873
10. Imai T., Taketani M., Shii M., Hosokawa M., and Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab. Dispos. 34 (2006) 1734-1741